302 related articles for article (PubMed ID: 25748606)
1. Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.
Eriksen M; Jensen DH; Tribler S; Holst JJ; Madsbad S; Krarup T
Diabetologia; 2015 May; 58(5):920-8. PubMed ID: 25748606
[TBL] [Abstract][Full Text] [Related]
2. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
[TBL] [Abstract][Full Text] [Related]
3. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
5. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Højberg PV; Vilsbøll T; Rabøl R; Knop FK; Bache M; Krarup T; Holst JJ; Madsbad S
Diabetologia; 2009 Feb; 52(2):199-207. PubMed ID: 19037628
[TBL] [Abstract][Full Text] [Related]
6. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
7. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
8. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
[TBL] [Abstract][Full Text] [Related]
9. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Aaboe K; Knop FK; Vilsboll T; Vølund A; Simonsen U; Deacon CF; Madsbad S; Holst JJ; Krarup T
J Clin Endocrinol Metab; 2009 Feb; 94(2):603-8. PubMed ID: 19050053
[TBL] [Abstract][Full Text] [Related]
10. The effect of age and glycemic level on the response of the beta-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin.
Meneilly GS; Ryan AS; Minaker KL; Elahi D
J Clin Endocrinol Metab; 1998 Aug; 83(8):2925-32. PubMed ID: 9709971
[TBL] [Abstract][Full Text] [Related]
11. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
[TBL] [Abstract][Full Text] [Related]
12. Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass.
Dirksen C; Bojsen-Møller KN; Jørgensen NB; Jacobsen SH; Kristiansen VB; Naver LS; Hansen DL; Worm D; Holst JJ; Madsbad S
Diabetologia; 2013 Dec; 56(12):2679-87. PubMed ID: 24048673
[TBL] [Abstract][Full Text] [Related]
13. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men.
Pilgaard K; Jensen CB; Schou JH; Lyssenko V; Wegner L; Brøns C; Vilsbøll T; Hansen T; Madsbad S; Holst JJ; Vølund A; Poulsen P; Groop L; Pedersen O; Vaag AA
Diabetologia; 2009 Jul; 52(7):1298-307. PubMed ID: 19288077
[TBL] [Abstract][Full Text] [Related]
14. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
[TBL] [Abstract][Full Text] [Related]
15. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
16. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
17. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
19. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
[TBL] [Abstract][Full Text] [Related]
20. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
